Recursion Pharmaceuticals, Inc.
RXRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRecursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation,. With a market capitalization of $1.84B, it sits in small-cap territory. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Market Cap
$1.84B
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
-3.84
EPS (TTM)
$-1.00
EPS (Fwd)
$-0.89
ROE
-56.6%
ROA
-27.3%
Cash
$545.7M
Total Debt
$66.6M
Free CF
-$219.5M
52W Change
-20.0%
Annual Financials
Cash vs Debt
Where RXRX stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, RXRX finished 0.88% above its 150-day moving average ($3.41) and 6.52% below its 200-day moving average ($3.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RXRX overbought or oversold?
At the August 28, 2026 close, RXRX's RSI(14) was 56.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Recursion Pharmaceuticals, Inc. holds $545.7M in cash against $66.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$219.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -56.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $39.7M (2022) to $74.3M (2025), reflecting a 87% increase over the period.
With cash comfortably exceeding debt, RXRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing RXRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.